Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4182022 | L'Encéphale | 2010 | 10 Pages |
Abstract
At entry, 37.4Â % were receiving monotherapy while 27.3Â % received a combined therapy. All patients received treatment for their manic / mixed episode, either in combination (59.2Â %) or in monotherapy (40.8Â %). Atypical antipsychotics were more often prescribed in association (34.0Â % of subjects) than in monotherapy (21.1Â %). In patients treated in monotherapy, atypical antipsychotics were the most often prescribed drug (51.9Â %). Results showed an improvement within both monotherapy and combination therapy in effectiveness measures at week 12. After 12Â weeks, 31.3Â % were considered recovered and 67.9Â % did not relapse. These results confirm current data on co-morbidities and give information on treatment for bipolar patients at three months of follow-up. The long-term evaluation of the French EMBLEM cohort - 12, 24Â months and up to five years - is presently ongoing.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Psychiatry and Mental Health
Authors
J.-M. Azorin, A. Luquiens, E. Aubrun, C. Reed, I. Gasquet, M. Lukasiewicz,